Search Within

Joachim Yahalom

  1. "Anita Kumar"
Formats
  1. Meeting Abstract (24)
  2. Journal Article (14)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (40)
  2. Department of Medicine (40)
  3. Hematologic Malignancies, Division of (40)
  4. Lymphoma (40)
  5. Radiation Oncology, Department of (40)
  6. Survivorship Research (40)

More Groups

People
  1. Anita Kumar (40)
  2. Andrew Zelenetz (38)
  3. Ariela Noy (37)
  4. Paul Hamlin (37)
  5. Alison Moskowitz (35)
  6. Maria Palomba (34)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (7)
  4. 2022 (3)
  5. 2021 (6)
  6. 2020 (4)

More Years

Publications
  1. Blood (16)
  2. Hematological Oncology (8)
  3. Journal of Clinical Oncology (4)
  4. Blood Advances (3)
  5. Haematologica (3)
  6. Blood Cancer Journal (2)

More Publications

Publishers
  1. American Society of Hematology (19)
  2. Wiley Blackwell (8)
  3. American Society of Clinical Oncology (4)
  4. Ferrata Storti Foundation (3)
  5. Nature Publishing Group (2)
  6. Elsevier Inc. (1)

More Publishers

Results (40)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Dose and/or volume reduction using consolidation volume radiation therapy (CVRT) lowers dose to heart and lungs in early-stage Hodgkin lymphoma patients with bulky disease
    Meeting Abstract

    Yang, J. C.; Kumar, A.; Chapman, K. L.; Burleson, S.; Huang, C.; Constine, L. S.; Hoppe, R. T.; Dandapani, S.; Straus, D. J.; Moskowitz, C. H.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD chemotherapy followed by ISRT: A safe primary treatment regimen for early-stage, unfavorable Hodgkin lymphoma
    Meeting Abstract

    Yang, J. C.; Kumar, A.; Chapman, K. L.; Constine, L. S.; Moskowitz, C. H.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2016)

    Fulltext@MSK | Save
  • Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes
    Journal Article

    Kumar, A.; Burger, I. A.; Zhang, Z.; Drill, E. N.; Migliacci, J. C.; Ng, A.; LaCasce, A.; Wall, D.; Witzig, T. E.; Ristow, K.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save